Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amarin

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

- PMLiVE

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali

- PMLiVE

NICE recommends MSD’s diabetes drug Steglatro

MSD offering lowest price to win share of SGLT-2 inhibitor market

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

Suggests Orkambi row has undermined confidence in NICE process

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

Biomarin

NICE knocks back BioMarin’s Batten disease drug

£500,000 list price too high without long-term data, says watchdog

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links